EC grants marketing authorization for Amgen's XGEVA to prevent skeletal-related event
Amgen today announced that the European Commission (EC) has granted marketing authorization for XGEVA (denosumab) for the prevention of skeletal-related events (SREs) in adults with bone metastases from solid tumors.